Aspirin for primary prevention of cardiovascular disease: a review of recent literature and updated guideline recommendations

References

• Virani SS, Alonso A, Benjamin EJ, et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2020 update: a report from the American heart association. Circulation. 2020 Mar 3;141(9):e139–596.
   PubMed Web of Science ®Google Scholar
• Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014 July 1;63(25Pt B):2935–2959.
   PubMedGoogle Scholar
• Bibbins-Domingo K. U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement. Ann Intern Med. 2016 June 21;164(12):836–845.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes—2018. Diabetes Care. 2018 Jan;41(Supplement 1):S86–S104.
   PubMedGoogle Scholar
• Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019Sept10;74(10):1376–1414.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes—2019. Diabetes Care. 2019 Jan;42(Supplement 1):S103–S123.
   PubMedGoogle Scholar
• American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes—2020. Diabetes Care. 2020 Jan;43(Supplement 1):S111–S134.
   PubMedGoogle Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes and cardiovascular diseases developed in collaboration with EASD. Eur Heart J. 2020 Jan 7; 41(2):255–323.
   PubMed Web of Science ®Google Scholar
• Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018Sept22;392(10152):1036–1046.
   PubMed Web of Science ®Google Scholar
• ASCEND Study Collaborative Group. Bowman L, Mafham M, Wallendszus K, et al. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018 Oct 18;379(16):1540–1550.
   PubMed Web of Science ®Google Scholar
• ASCEND Study Collaborative Group. Bowman L, Mafham M, Wallendszus K, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018 Oct 18;379(16):1529–1539.
   PubMed Web of Science ®Google Scholar
• Aung T, Haynes R, Barton J, et al. ASCEND Study Collaborative Group. Cost-effective recruitment methods for a large randomised trial in people with diabetes: a study of cardiovascular events in diabetes (ASCEND). Trials.2016 June 13;17(1):286.
   PubMedGoogle Scholar
• Bowman L, Mafham M, Stevens W, et al., ASCEND Study Collaborative Group. ASCEND: a study of cardiovascular events in diabetes: characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes. Am Heart J. 2018 Apr;198:135–144.
   PubMed Web of Science ®Google Scholar
• ASPREE Investigator Group. Study design of ASPirin in reducing events in the elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials. 2013 Nov 1;36(2):555–564.
   PubMed Web of Science ®Google Scholar
• Nelson MR, Reid CM, Ames DA, et al. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in reducing events in the elderly (ASPREE) pilot study. Med J Aust. 2008 July 21;189(2):105–109.
   PubMed Web of Science ®Google Scholar
• McNeil JJ, Wolfe R, Woods RL, et al., ASPREE Investigator Group. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018 Oct 18;379(16):1509–1518.
   PubMed Web of Science ®Google Scholar
• McNeil JJ, Woods RL, Nelson MR, et al. ASPREE Investigator Group. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med.2018 Oct 18;379(16):1499–1508.
   PubMed Web of Science ®Google Scholar
• McNeil JJ, Nelson MR, Woods RL, et al. ASPREE Investigator Group. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med.2018 Oct 18;379(16):1519–1528.
   PubMed Web of Science ®Google Scholar
• Wolfe R, Murray AM, Woods RL, et al. The aspirin in reducing events in the elderly trial: statistical analysis plan. Int J Stroke. 2018 Apr;13(3):335–338.
   PubMed Web of Science ®Google Scholar
• McNeil JJ, Woods RL, Nelson MR, et al. ASPREE Investigator Group. Baseline characteristics of participants in the ASPREE (ASPirin in reducing events in the elderly) study. J Gerontol A Biol Sci Med Sci.2017 Oct 12;72(11):1586–1593.
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ (ATT) Collaboration. Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009 May 30;373(9678):1849–1860.
   PubMed Web of Science ®Google Scholar
• An SJ, Kim TJ, Yoon B-W. Epidemiology, risk factors, and clinical features of intracerebral hemorrhage: an update. J Stroke. 2017 Jan;19(1):3–10.
   PubMed Web of Science ®Google Scholar
• Cea Soriano L, Lanas A, Soriano-Gabarró M, et al. Incidence of upper and lower gastrointestinal bleeding in new users of low-dose aspirin. Clin Gastroenterol Hepatol. 2019 Apr;17(5):887–895.
   PubMed Web of Science ®Google Scholar
• Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA. 2019 Jan 22;321(3):277–287.
   PubMed Web of Science ®Google Scholar
• García Rodríguez LA, Lanas A, Soriano-Gabarró M, et al. Low-dose aspirin and risk of upper/lower gastrointestinal bleeding by bleed severity: a cohort study with nested case-control analysis using primary care electronic health records from the United Kingdom. Ann Med. 2019 Mar;51(2):182–192.
   PubMed Web of Science ®Google Scholar
• O’Brien CW, Juraschek SP, Wee CC. Prevalence of aspirin use for primary prevention of cardiovascular disease in the United States: results from the 2017 National Health Interview Survey. Ann Intern Med. 2019 July;23:596–598. [ePub ahead of print].
   Google Scholar
• Selak V, Jackson R, Poppe K, et al. Personalized prediction of cardiovascular benefits and bleeding harms from aspirin for primary prevention: a benefit-harm analysis. Ann Intern Med. 2019 Oct 15;171(8):529–539.
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Kim S, Piccini JP, et al. ORBIT-AF Investigators and Patients. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF) registry. Circulation.2013 Aug 13;128(7):721–728.
   PubMed Web of Science ®Google Scholar